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Abstract
Background
Precision medicine aims to combat the variability of the therapeutic response to a given
medicine by delivering the right medicine to the right patient. However, the application of
precision medicine is predicated on a prior quantitation of the variance of the reference
range of normality. Airway pathophysiology provides a good example due to a very variable
first line of defence against airborne assault. Humans differ in their susceptibility to inhaled
pollutants and pathogens in part due to the magnitude of trans-epithelial resistance that
determines the degree of epithelial penetration to the submucosal space. This initial ‘set-
point’may drive a sentinel event in airway disease pathogenesis. Epithelia differentiated in
vitro from airway biopsies are commonly used to model trans-epithelial resistance but the
‘reference range of normality’ remains problematic. We investigated the range of
electrophysiological characteristics of human airway epithelia grown at air-liquid interface in
vitro from healthy volunteers focusing on the inter- and intra-subject variability both at base-
line and after sequential exposure to drugs modulating ion transport.
Methodology/Principal Findings
Brushed nasal airway epithelial cells were differentiated at air-liquid interface generating
137 pseudostratified ciliated epithelia from 18 donors. A positively-skewed baseline range
exists for trans-epithelial resistance (Min/Max: 309/2963 Ωcm2), trans-epithelial voltage
(-62.3/-1.8 mV) and calculated equivalent current (-125.0/-3.2 μA/cm2; all non-normal,
P<0.001). A minority of healthy humans manifest a dramatic amiloride sensitivity to voltage
and trans-epithelial resistance that is further discriminated by prior modulation of cAMP-
stimulated chloride transport.
Conclusions/Significance
Healthy epithelia show log-order differences in their ion transport characteristics, likely
reflective of their initial set-points of basal trans-epithelial resistance and sodium transport.
Our data may guide the choice of the background set point in subjects with airway diseases
and frame the reference range for the future delivery of precision airway medicine.
PLOS ONE | DOI:10.1371/journal.pone.0149550 February 29, 2016 1 / 20
OPEN ACCESS
Citation: Tosoni K, Cassidy D, Kerr B, Land SC,
Mehta A (2016) Using Drugs to Probe the Variability
of Trans-Epithelial Airway Resistance. PLoS ONE 11
(2): e0149550. doi:10.1371/journal.pone.0149550
Editor: Neeraj Vij, Central Michigan University
School of Medicine, UNITED STATES
Received: July 10, 2015
Accepted: February 2, 2016
Published: February 29, 2016
Copyright: © 2016 Tosoni et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was funded by the Myrovlytis
Trust (#804824) awarded to AM and SCL (www.
myrovlytistrust.org) and the early work was funded by
the Russell Trust. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
The ciliated airway epithelium is the first line of host defence against airborne assault [1]. One
measure of the integrity of this epithelial barrier is the product of its electrical (ohmic) resis-
tance and epithelial surface area, known as trans-epithelial electrical resistance (TER; Ocm2).
The clinical relevance is that TER dysregulation may drive disease pathogenesis. For example,
it has been proposed that chronicity in asthma may be cued by an initial genetic and or envi-
ronmental propensity that lowers TER, facilitating epithelial penetration that subsequently
drives irreversible airway remodelling [2]. The clinical importance of TER is further illustrated
by recent data suggesting that cigarette smoke, inhaled pollutants or acid exposure due to gas-
tro-oesophageal reflux can all dysregulate tight junctional proteins by signalling through ion
channels and/or acid sensors [3–5]. Furthermore, in Cystic Fibrosis (CF), mutation of one api-
cal channel, the CF transmembrane conductance regulator (CFTR), disturbs a regulatory (pro-
teostasis) network that, inter alia, controls TER [6]. Additionally, understanding TER
regulation may also be important for new therapies aimed at rare inherited airway diseases,
where a better understanding of the means to lower TER might aid penetration of agents tar-
geted to repairing innermost progenitor cells that renew damaged airways [7,8]. Here, we focus
on TER in primary human nasal epithelial (HNE) cells grown at air-liquid interface (ALI) with
the caveat that many different methods exist to culture such cells [9–11] but as yet, open stan-
dard operating procedures that define a “normal” range of values for TER are not available.
Perhaps a better term might be reference range because ‘normal’ is not agreed. Moreover,
transparency of reporting is not aided by the polar opposite opinions about the relevance of the
magnitude of TER measured in a given in vitro experiment [12]. These decade old controver-
sies are unresolved which prompted us to review the factors underlying the plasticity of TER
values generated by human nasal epithelia reconstituted in vitro derived from apparently
healthy volunteers. Hence, our aim was firstly, to publish our reference range for the distribu-
tion of baseline TER values across nasal turbinate derived ALI cultures; secondly, to determine
the range of TER across multiple ALIs derived from a given volunteer and thirdly, to quantitate
drug-induced changes in TER after sequential manipulation of sodium and chloride ion trans-
port using two differently ordered protocols (chloride transport stimulation after cAMP eleva-
tion followed by sodium transport inhibition, or vice versa). The data suggest that baseline
TER is not normally distributed with dichotomous responses to drugs targeting ion channels.
We propose measures to normalise the wide range of TER both at baseline and characterise the
differential response to drugs acting on ion transport proteins such as the epithelial sodium
channel (ENaC) and CFTR.
Materials and Methods
Materials
Penicillin/Steptomycin (#15070), Bovine Collagen I (#A10644), HBSS (#14025) and DMEM
high glucose (#41966) were from Invitrogen (Paisley, Scotland, UK). Primocin (#ant-pm-1)
was from Invivogen (Toulouse, France). CellnTec media (#CnT-17) was from CalTag Medsys-
tems (Buckingham, England, UK). PromoCell Airway Epithelial Growth media (#C21160) was
from PromoCell (Heidelberg, Germany). Corning Costar Snapwells and Transwells (#3450
and #3407 respectively) were from VWR (Lutterworth, England, UK). Accutase (#A6964), all-
trans retinoic acid (#R2625), forskolin (#F6886), CFTR inhibitor Inh172 (#C2992), amiloride
(#A7410), benzamil (#B2417) and BSA (#A7906) were from Sigma-Aldrich (Poole, England,
UK). Monoclonal antibody anti-acetylated alpha tubulin (# ab24610, 1:1000) was from Abcam
(Cambridge, England, UK). Cell Signalling polyclonal anti-Z0-1 (# 07D12, 1:1000) was from
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NEB (Hitchin, England, UK). Alexa Fluor 488 donkey anti-mouse IgG (#A21202, 1:2000) and
Alexa Flour 555 donkey anti-rabbit IgG (# A31572, 1:2000) were from Life Technologies (Pais-
ley, Scotland, UK). Hydromount (#HS-106) was from National Diagnostics (Hessle, England,
UK).
Brush Biopsies
Nasal brushings from the inferior turbinate bones were performed on 18 healthy volunteers
(12 male, 6 female, age range: 18–40 (mean 29) years) as previously described [13–15]. The
brushing procedure was approved by East of Scotland Research Ethics Service (EoSRES) REC1
(REC reference 12/ES/0081 Protocol number 2011RC20), and informed written consent was
obtained from all subjects (A4 documentation signed and retained).
Cell culture
The cell culture protocol is based on a combination of different approaches [16–18] leading to
our standard operating protocol (SOP); where reference is made to additional notes these may
be found in the S1 File. After initial screening studies using different cell culture media (n>30
donors, data not shown) we identified two commercially available serum-free media that effi-
ciently propagated cells on T25 collagen-coated dishes. Both media were used as per manufac-
turer’s recommendation and additionally supplemented with 2% Penicillin/Streptomycin and
100μg/ml Primocin. From this initial work, a culturing methodology was optimized. Brushings
were all collected in phosphate buffered saline (PBS) at room temperature and centrifuged at
122×g for 4 min. The cell pellet was washed once with PBS and then the cells were seeded onto
flasks that were collagen-coated (Bovine Collagen I- note-1) at 5 μg/cm2 in PBS for at least 1
hour at 37°C. Prior to cell seeding, the plate surface was washed twice with PBS. Typically, each
pooled brushing (from six nasal scrapes, three per side) was sufficient to seed two T25 flasks
(note-2 to 4). Cells were firstly seeded in CellnTec media, for 48h (adherent cells were desig-
nated P01) on collagen-coated T25 flasks, after which the supernatant containing the non-
adherent cells was centrifuged (4 min at 122×g) and the cells were resuspended in the Promo-
Cell Airway Epithelial Growth media, and seeded in T25 flasks for another 48h (attached cells
then designated P03). After that time, the supernatant containing the non-adherent, and
mostly spinning ciliated spheroids was transferred into a new flask and used for other experi-
ments while fresh CellnTec media was added back to the original P03 T25s. The attached P01/
P03 cells were grown until 80–90% confluent (typically 7 to 10 days post-seeding, note-5), and
exposed to a cell detachment solution (Accutase, 1ml per T25), monitoring until all cells
detached. Cells were then re-seeded on to collagen-coated Transwell or Snapwell inserts,
depending on the nature of the subsequent experiments. In general, from two T25 plates (either
P01 or P03), 12 Snapwells and 2 Transwells could be seeded (note-6). The cells were grown in
CellnTec media submerged until confluence was reached (typically after 2–3 days) and then
the medium was removed on the apical side to establish ALI. Pro-differentiation media, which
consisted of 1:1 ratio of DMEM high glucose and PromoCell containing 1X concentration of
PromoCell supplements plus 50nM all-trans retinoic acid, was added to the basolateral side.
Medium was changed in the lower chamber of the inserts and the cells were washed apically
with cell media every two days (note-7 and 8). Trans-Epithelial Electric Resistance (TEER) was
assessed in situ every three days using a chopstick Epithelial Voltohmmeter (EVOM2, World
Precision Instruments -WPI, Stevenage, England, UK) and inserts with TEER>400 O/insert
(note 9) were used for Ussing Chamber experiments. Ciliogenesis was typically observed after
*3 weeks at ALI with evidence of tight junction formation.
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Ussing Chamber
Snapwell supports with confluent and resistive cells, were mounted in an Ussing chamber
and bathed both apically and basolaterally with Hank’s Balanced Salt Solution (HBSS, com-
position mM: 137.93 NaCl, 4.17 NaHCO3, 1.26 CaCl2, 0.49 MgCl2, 0.41 MgSO4, 5.33 KCl,
0.44 KH2PO4, 0.34 Na2HPO4, 5.56 D-Glucose), bubbled with 5%CO2/ 95%O2 at 37°C.
Experiments were performed as described in [19]. Briefly, the epithelia were maintained
under open-circuit conditions and the spontaneous trans-epithelial potential difference (V)
was monitored (DVC-1000 Voltage/Current Clamp, WPI) and recorded (4 Hz) electronically
(ADI Powerlab Interface and associated software; AD Instruments, Chalgrove, Oxfordshire,
UK). Experiments were initiated once V had stabilized (20–30 min) then standard pulses of
trans-epithelial current (20 sec, −10 μAcm−2) were injected every 40 sec, leaving the epithelia
to stabilize again (10–15 min) before adding any drug. The spontaneous voltage generated by
the cells is reflective of the in vivo lumen-negative voltage when an electrode is placed on a
nasal turbinate and connected in series with a voltmeter attached to another electrode in
basolateral space. This universally observed negative deflection of the turbinate surface elec-
trode in humans is thought to be due to positively charged sodium ions moving towards the
blood inferred by the near collapse of that voltage when the sodium blocker amiloride is
added to the perfusate bathing the turbinate, or in the Ussing chamber equivalent, when
amiloride is added to the apical side of the cultured cells. We parameterised the role of
sodium transport by cation substitution experiments in order to prove that the voltage at
baseline was sensitive to sodium withdrawal (with N-methyl-D-glucamine, NMDG, S1 Fig).
Next, we undertook pilot experiments showing that amiloride and the high affinity ENaC
blocker benzamil at a 10-fold lower dose (1μM, 10 min) were electrophysiologically indistin-
guishable (data not shown). Thereafter amiloride was used as the most cost effective, widely
used inhibitor thereby facilitating others to compare their protocols against our reference
range. Additionally, two different concentrations of the CFTR inhibitor gave the same inhibi-
tion of forskolin-stimulated ion transport (data not shown).
Drug addition regimes
We determined how TER, V and the ratio of V/TER [IEq] changed under two drug regimes in
which drugs where added sequentially, without any washout.
1. To raise cAMP, forskolin (FSK) was added both apically and basolaterally at 10μM for 15
min, followed by the CFTR blocker, CFTRInh172 apically either at 8.0 or 4.0 μM for 15 min.
Amiloride (AMI) was finally added apically at 10μM for 10 min.
2. Vice versa, such that amiloride was added first followed by forskolin and CFTRInh172, condi-
tions as above.
The important caveat to the ion transport data reported herein is that the results reflect
symmetrical apical and basolateral sodium chloride (137.9 mM) as this eliminates differences
across the paracellular space. For each ALI, V, TER and [IEq] values (measured or calculated)
during 4 min window out of the 10–15 min initial stable state were averaged and termed
Baseline (BAS.). The same approach was applied for the values after amiloride and
CFTRInh172 addition. For the means with forskolin, the time window for averaging was
increased to 6 min.
Additional information relating to brush biopsies, cell culture (SOP and immunofluores-
cence) and Trans-epithelial resistance calculation can be found in the S1 File.
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Statistics
Analysis was performed with GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA,
USA) and results expressed as means ± errors as specified in Fig legends. Data were compared
using unpaired Student’s t-test or one-way ANOVA. Where tests of normality (Shapiro-Wilk)
failed, data were analysed using non-parametric tests (Mann-Whitney U test and Kruskal-Wal-
lis ANOVA + Dunn’s multiple comparison test). Groups of data were considered to be signifi-
cantly different if P<0.05.
Results
Our final standard operating protocol (Fig 1A, top panel, P01 and P03 submerged ‘source’ cul-
tures, Fig 1B) for the differentiation of human nasal epithelia was applied to 18 healthy donor
biopsies. This SOP for differentiation at ALI generated ciliated HNE cultures, with spontane-
ous apical negative voltage (resistive after 15–20 days in culture) in>98% of brushings. A typi-
cal fully differentiated epithelium is shown in Fig 1C demonstrating both cilia and tight
junction formation.
Baseline electrophysiological values
When ALI cultures developed resistance, each was mounted in an Ussing chamber with sym-
metrical solutions bathing apical and basolateral surfaces. Fig 2 shows the range of transport
parameters at baseline from 137 ALI cultures (n = 18 volunteers). The variability of V, calcu-
lated resistance (TER) and equivalent current (V/TER[IEq]) values is shown in Fig 2A, 2B and
2C respectively (summary in panel E).
Fig 1. Human nasal epithelia in vitro reconstitution. (A) Schematic representation of cell culture protocol for expansion and differentiation of HNEs for
Ussing Chamber experiments. (B) Typical HNEmonolayer obtained after 7–10 days in culture on collagen-coated flasks. (C) Immunofluorescence of ALI
differentiated epithelia: representative acetylated tubulin (green) and ZO-1 (red) with DAPI counterstain (blue) performed after Ussing chamber experiment;
3D reconstruction from z-stack in adjacent left and top panel.
doi:10.1371/journal.pone.0149550.g001
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These data also show no relationship between initial voltage (V) and calculated TER
(Fig 2D). The baseline TER values were highly scattered with a*9-fold difference between the
lowest and highest resistances (compare Min and Max Fig 2E), with most TER values clustered
in the 500–800 Ocm2 range as reflected in the ‘Christmas tree’ shape of the distributions in
Fig 2B (see also frequency distribution graphs in S2A Fig showing that nearly 60% of ALIs have
TER between 300 and 900 Ocm2, 25% of the total in the range 500–700). Statistical analysis
confirmed the non-normal distribution for all the parameters (P<0.001). This asymmetry at
an ALI level (which persisted after logarithmic transformation of voltage and TER but not cal-
culated current, data not shown) resulted from very high values in a minority of ALIs consis-
tent with the idea that these have electrical properties that differ from the majority.
This finding that log transformation failed to normalise TER and voltage values prompted
re-clustering at a volunteer level to test the hypothesis that high values were a characteristic of
a given donor’s cells. First, we ranked the TER at baseline by donors mean values in ascending
order (abscissa Fig 3B) and cross compared the spread of voltage and equivalent current
(respectively Fig 3A and 3C).
As shown in Fig 2D, it was not possible given a starting voltage to predict the corresponding
TER. Interestingly only a minority of ALIs from a single individual had a range of voltage val-
ues that spanned the extremes of the population distribution (e.g. donor C, H, L and N in
Fig 2. Baseline electrophysiological values from Ussing chamber experiments. (A-C). Box plots
showing baseline electrophysiological values. Minimum, maximum (whiskers) and 25th/75th percentile,
median (box line) and mean (cross) are highlighted. (D) Plot of initial V against TER. (E) Table of basic
statistical analysis of the data shown in A-C.
doi:10.1371/journal.pone.0149550.g002
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Fig 3. Electrophysiological values on an individual donor basis (A-R). Box plots per donor highlighting
minimum, maximum (whiskers) and 25th/75th percentile and median (box). Donors arranged in ascending
order ranked by mean values of TER in (B) with number of ALIs per donor above the boxes. These are
compared with either (A) voltage, (C) [Ieq] and (D) time at ALI.
doi:10.1371/journal.pone.0149550.g003
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Fig 3A). Fig 3D shows the length of time in culture at ALI in differentiation media to determine
whether this could be used to predict the spread of the baseline values shown above.
As shown, there is no discernible relationship and the intra-donor variability cannot there-
fore be explained by the different length of time in which the cultures have been grown prior to
Ussing Chamber analysis. Our data suggest that some individual donors vary significantly in
their baseline TER (Fig 3B). In summary the non-normal distribution of the TER values is best
explained by the observation that there are a greater number of individuals than expected at
the extremes of the distribution. This means there are more individuals with a very low or high
TER compare to a normal distribution as shown in S2 Fig.
Drugs as probes to study TER plasticity
Next, we investigated how TER values for a given ALI change in response to the sequential
addition of drugs that elevate cyclic AMP (forskolin, FSK), inhibit sodium transport (amilor-
ide, AMI), or inhibit CFTR (inhibitor CFTRInh172). The rationale for the use of these drugs is
described in the methods. We used two different orders of sequential addition of drugs (Fig 1A
lower panel), as exemplified by the typical experimental traces in Fig 4A-I and 4A-II that also
are reflective of the wide range of baseline voltages shown in Fig 2 (see also S3A Fig and
Table A in S1 File for volunteers Q, C, J).
The sequential drug regime I was applied to 44 ALI cultures from 13 donors (Fig 4B-I and
4C-I) while drug regime II was tested using 81 ALI cultures from 18 donors (Fig 4B-II and 4C-II).
The baseline TER values were similarly highly scattered (Min andMax Fig 4C-I and 4C-II). With
drug regime I, ENaC was inhibited after pharmacological opening and closure of CFTR. Forskolin
decreased TER by ~30% with respect to baseline, this effect being mostly counteracted by
CFTRInh172 (increase up to ~90% of BAS.). Subsequent amiloride addition raised TER by ~30%
respect to baseline, also revealing a minority of ALI cultures whose resistance rose into the>3000
Ocm2 (+AMI in Fig 4B-I also S2 Fig, panel B-I for changes in relative frequency distribution of val-
ues). Variability of response was reflected in the 13-fold difference between the Min andMax val-
ues (+AMI, Fig 4C-I). This rise in a minority of ALIs is an amiloride-driven effect and not an
artefact of the regimen since it recurred when regime II was applied (no prior chloride transport
modulation, Fig 4B-II and 4C-II).
Upon amiloride addition TER increased by ~40% with respect to baseline; again very high
resistances were observed in a minority of ALIs (see also S2 Fig, panel B-II). Forskolin decreased
TER to ~90% of BAS., while CFTRInh172 increased TER to ~35% above baseline. There was a con-
siderable rise in the median value in the presence amiloride alone (from 815 to 1201), which was
not observed in drug regime I when amiloride was added after forskolin and CFTRInh172. This
suggests that amiloride exposure after CFTR modulation was acting on the epithelium differently
with respect to TER when compared to amiloride administered alone. Non-parametric statistical
analysis demonstrated no significant difference between groups except +FSK vs +AMI in drug
regime I. Contrastingly, drug regime II showed no significant difference between BAS. and +FSK,
or between +AMI and +CFTRInh172. See also S4 Fig (along with Tables E and F in S1 File, for
mean data values) that shows how TER changes for all of the ALIs after the addition of drugs and
also for the individual donor responses suggesting that certain individuals respond differently to
drug administration. This variability prompted a deeper analysis.
Initial baseline vs rolling baseline approach to data analysis
These analytical complexities prompted us to re-examine drug induced effects on TER using a
different approach reflective of the starting value of TER. First, we determined whether the
baseline TER was predictive of the degree of change upon drug addition (Fig 5).
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Initially, we plotted the drug-induced TER values against a common starting baseline TER,
for each regime (Fig 5A–5D, Drug regime I and II). The hypotenuse of each shaded triangular
area in each panel of Fig 5 is the line of identity between the TER response to a drug (ordinate)
Fig 4. Ussing chamber ion transport analysis. (A-I, A-II) Two different drug regimes (I and II) were used and typical representative traces from two donors
each are shown. (B-I, C-I) TER values obtained applying drug regime I with their Table of basic statistical analysis. Similarly (B-II, C-II) show the data
obtained applying drug regime II. Error bars: mean ± SD; Kruskal-Wallis ANOVA + Dunn’s multiple comparison test: *P<0.05; **P<0.01, ***P<0.001.
doi:10.1371/journal.pone.0149550.g004
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Fig 5. Drug induced effect on TERwith respect to the initial baseline. TER values at baseline are plotted
against values obtained after the cumulative addition of the different drugs. The hypotenuse of the shaded
triangular area represents the line of identity, while magnifications are shown in the box inserts. (A-I) The
Variability of Trans-Epithelial Airway Resistance
PLOS ONE | DOI:10.1371/journal.pone.0149550 February 29, 2016 10 / 20
and the baseline (abscissa), the latter being the start value of TER. It can be seen that in drug
regime I, forskolin induced a fall in TER irrespective of the magnitude of the baseline TER (Fig
5A-I, inset). Interestingly CFTRInh172 restored the TER back to the line of identity suggesting
that the forskolin effect in lowering TER was largely driven by CFTR activation. Under these
conditions, AMI induced a rise in TER to above the line of identity, but only for a minority of
ALIs (Fig 5C-I) suggesting that there may exist two populations of amiloride-insensitive (data
near the shaded area) and amiloride-sensitive ALIs (data lying outside the confidence intervals
in the main Fig 5C). This is further exemplified in Fig 5D-I, where the low amiloride respond-
ers (LOW, closed grey circles) have been separated from the high responders (HIGH, open
squares). The cut off to determine our division of this population into two groups was based on
whether the fold increase of TER was above or below the slope value in Fig 5C-I. To test the
validity of this arbitrary choice, we repeated this analysis with drug regime II.
On this occasion however, amiloride induced a rise in TER for all ALIs, but of different
magnitude enabling the discernment of two groups of responders, LOW and HIGH, grouped
by their fold rise in TER i.e. an increase being above or below the mean of the population (Fig
5A-II and 5B-II). Once again forskolin drove the TER below the line of identity (but only for
LOW responders, see regressions in Table B in S1 File) and the two groups of LOW and HIGH
responders remained quite distinct even when the CFTRInh172 was superimposed (Fig 5C-II
and 5D-II). This analysis shows that the changes in TER after the addition of drugs are inde-
pendent of the baseline magnitude and the major changes that occur upon amiloride addition
are specific to this compound, but partially affected by the order of its administration with
respect to modulation of anion transport.
Next, we re-plotted the data but now assuming that the TER value in the presence of a given
drug generated a new drug-induced baseline with each addition (Fig 6).
Using this rolling baseline approach, in Fig 6B-I, CFTRInh172 doubles the slope (compare
with panel A-I). Subsequent addition of amiloride increases the slope yet further (Fig 6C-I),
and the two groups of LOW and HIGH responders are now discrete (Fig 6D-I). In regime II,
where amiloride is added first, differences between the LOW and HIGH groups were more dif-
ficult to discern when more than one drug was present showing differences in the effect of
CFTRInh172 but not forskolin. (Fig 6B-II and 6C-II, see slope t-test, Table C in S1 File). S5 Fig
shows the data redrawn for ease of comparison. First, the baseline resistance is used as a com-
mon reference point (S5 Fig, panels A-I and A-II). Alternatively, each drug-induced resistance
value is used as a rolling reference point where the focus is on the individual effect of a given
drug (S5 Fig, panels B-I and B-II).
The response patterns are qualitatively different but in each case outliers become apparent
as certain drugs are added, with each inhibitor of ion transport showing the greatest outlier
generating effect (see also S6 Fig for a quantitative analysis of the range of outliers). Earlier, we
had found that individual donors’ data were reflective of ALI data as a whole. Hence, we re-
initial baseline TER values (closed grey circles) are plotted against the values obtained after addition of FSK
(n = 44), (B-I) FSK+CFTRInh172 (n = 44) and (C-I) FSK+CFTRInh172+AMI (n = 44); line of regression is shown
as a dashed line with 99% CI (grey vertical bars). In D-I same data as in C-I showing two distinct populations
of amiloride responders designated as LOW (closed grey circles-black dashed regression line +99%CI
vertical bars, n = 31) and HIGH (open squares, black regression line +99%CI dotted line, n = 13). (A-II) The
initial baseline TER values (closed grey circles) are plotted against the values obtained after addition of
amiloride; line of regression is shown as a dashed line with 99% CI (grey vertical bars). In B-II same data as in
A-II showing two distinct populations designated as LOW (n = 57) and HIGH (n = 24) amiloride responders.
Changes in TER with cumulative drug addition of (C-II) AMI+FSK (LOW n = 56, HIGH n = 24) and (D-II) AMI
+FSK+CFTRInh172 (LOW n = 56, HIGH n = 21). Additional regression and statistical analysis data are shown
in Table B in S1 File.
doi:10.1371/journal.pone.0149550.g005
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Fig 6. Drug induced effect on TERwith respect to the rolling baseline. TER values at each stage of the
drug regime chronologically are considered as baseline. The hypotenuse of the shaded triangular area
represents the line of identity while magnification is shown in the box inserts. (A-I) The initial baseline TER
values (closed grey circles) are plotted against the values obtained after addition of forskolin (n = 44). (B-I)
TER values +FSK are plotted against values after addition of CFTRInh172 (n = 44). (C-I) Values of TER with
CFTRInh172 plotted against values +AMI (n = 44); line of regression: dashed line +99%CI (grey vertical bars).
In D-I same data as in C-I showing two distinct populations of amiloride responders designated as LOW
(closed grey circles-black dashed regression line +99%CI vertical bars, n = 35) and HIGH (open squares,
black regression line +99%CI dotted line, n = 9). (A-II) The initial baseline TER values are plotted against the
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analysed the data at a volunteer level. Fig 7B-I shows that upon amiloride addition two distinct
groups of volunteers are revealed in regime I using the rolling baseline approach, whose exis-
tence is implied but not clearly discriminated using the other drug regime (+AMI Fig 7A-II
and 7B-II). For completeness we also show the mean responses when the reference is set to the
initial baseline TER (Fig 7A-I and 7A-II).
Our initial findings were that there was no relationship between baseline voltage and base-
line TER. However, when the initial voltage is plotted for a given ALI against its TER ratio
response to amiloride addition, we now observe a curvilinear relationship between the two
parameters (S7 Fig). Alternatively, plotting the logarithm of the initial voltage, two distinct
populations emerge, especially in drug regime II; and also in drug regime I but only when the
TER ratio is recalculated as +AMI/+CFTRInh172 (rolling approach, S7 Fig, panel D-I). Applying
the grouping as in Figs 5 and 6, the two populations of LOW and HIGH responders remain
distinct (Fig 8), but are more clear with drug regime II (Fig 8A-II, Table D in S1 File).
values obtained after addition of amiloride showing two distinct populations designated as LOW (n = 57) and
HIGH (n = 24) amiloride responders. (B-II) Amiloride values plotted against values +FSK (LOW n = 56, HIGH
n = 24). (C-II) Values after addition of forskolin plotted against values +CFTRInh172 (LOW n = 56, HIGH
n = 21). Additional regression and statistical analysis data are shown in Table C in S1 File.
doi:10.1371/journal.pone.0149550.g006
Fig 7. Donor-level analysis of TER ratio change upon drug addition. (A-I, A-II) Donors averaged ratios of
TER with drug regime I (N = 13) and II (N = 18) respectively, applying the initial baseline approach
highlighting the cumulative effect of the drugs. (B-I, B-II) Same data analysed applying the rolling baseline
approach to the TERmean values of the individual donors. Error bars: mean ± 95%CI.
doi:10.1371/journal.pone.0149550.g007
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These graphs show that the HIGH amiloride responders have higher baseline voltages.
Importantly, from the comparison of the groups obtained with either of the drug regimes and
the different analytical approaches (Figs 5 and 6), we observed that the outliers in the presence
of amiloride (HIGH responders, for example Fig 7B-I and 7A-II), belong to the same donors
irrespective of whether amiloride is added first or last (compare also donors with ratios above
1.5 for +AMI in S6 Fig, panel B-I and A-II). This suggests that healthy volunteers demonstrate
significantly different changes in TER in response to drugs such as amiloride that fall into
dichotomous groups after drug challenge.
Discussion
Many research groups use cultured nasal brushings to model airway function [9,20], albeit
with differences in opinion on the relevance of such biopsies [12,21], which is not surprising
given the many different protocols for their cell culture together with different methodologies
to assay bioelectrical properties [22]. Our results are comparable to the literature for either
nasal [16,23] or tracheal/bronchial [11,24] epithelial cells, and those from commercial sources
[25]. Our observed spread of values, i.e. intra-donor variability between ALIs from a given
Fig 8. Relationship between baseline voltage and response of TER after amiloride addition. Logarithm of baseline V plotted against ratio of TER upon
amiloride addition in drug regime I, applying the initial baseline (A-I), or the rolling baseline approach (B-I). In drug regime II (A-II), grouping produced a
significant difference between the two groups (LOW, n = 57; HIGH, n = 24). For both drug regimes, grouping was performed as in Figs 5 and 6. Additional
regression and statistical analysis data are shown in Table D, S1 File.
doi:10.1371/journal.pone.0149550.g008
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biopsy, is most likely caused by differences in the seeding composition of progenitors (Fig 1A),
since this variability cannot be explained by differences in the length of time in culture as
shown in Fig 3D. These causes are beyond the scope of the current paper but have been specu-
lated on recently [26]. Such TER variability poses a severe challenge for the very idea of normal
controls which in turn becomes a critical issue in the interpretation of disease findings and
especially when any therapy has to be personalised, also known as precision medicine [27].
First, we find a large range, irrespective of whether the mean or median values from a given
volunteer’s aggregated ALI data are studied. Second, our transport data are not normally dis-
tributed with voltages over a>30-fold range (-62.3/-1.8 mV), with an equivalent>9-fold
range of values for TER (from 309 to 2963 Ocm2) coupled to a minority of ALIs that have
drug responses which differ markedly from the rest. Third, this variability is likely not an in
vitro artefact because such a wide range is also found in vivo when nasal potential difference is
measured in apparently healthy volunteers [28,29] which is of clinical importance given that
this test has been proposed as a discriminant between disease and health [30]. Fourth, the vol-
unteers who have a higher response to amiloride are the same subjects irrespective of the order
of drug addition, suggesting that the degree of amiloride sensitivity is an intrinsic property of
an individual’s epithelium. Fifth, a high amiloride response, is not predictive of an equivalently
high response to forskolin plus CFTRInh172 (i.e. donor A vs R in S6 Fig). Sixth, there is no clear
relationship between baseline voltage and resistance (Fig 2D). This is not unexpected given the
complexity of the regulation of sodium transport across the airway epithelium [31] as the dom-
inant driver of baseline voltage coupled to the equivalent complexity of the dynamic regulation
of TER, with many independent studies showing an interaction between sodium and chloride
transport mediated by CFTR [32–34]. The combined data suggest that ion transport at baseline
and after sequential exposure to drugs both vary but amiloride-sensitivity as a marker of the
underlying sodium transport remains the major component. In fact amiloride reduced by
10-fold the reference range for the current transported by the epithelium (data not shown)
and, as might be expected, widens the TER range (Fig 4B and 4C). Importantly the order of
drug administration does not alter the width of the TER range (compare Fig 4C-I with 4C-II
and S2 Fig). Only 4 subjects have low values of TER after amiloride (B,D,E and G, below 1000
Ocm2, S4 Fig, panels B-I and B-II) but only two of them (E and G) have little change in TER
after its administration (see S6 Fig, TER Ratio near to 1).
From a disease perspective, the magnitude of TER has been reported to be important in the
pathogenesis of asthma [2] and future work will have to determine whether the starting values
of TER might determine the propensity of a given individual to develop clinically detectable
disease, for example after exposure to diesel particulates. Mechanistically, recent work has
shown that a number of genes alter the phenotype of Cystic Fibrosis [35,36] and some of these
are epithelial transporters whereas others are immune modulators. Co-inheritance of differ-
ences in such proteins are equally likely to be present in our normal volunteers and might
explain the background variability in the parameters reported in this paper. This idea is sup-
ported by the finding that magnitude of the forskolin current in the presence of amiloride, and
its subsequent level after the addition of the CFTR inhibitor, is also variable (data not shown).
Between donors, this means that the airway epithelium is reacting differently to the presence of
different drug combinations and care is needed in the choice of control subjects in a disease
setting.
We believe these are important considerations for personalized medicine, particularly when
choosing the best controls for a study.
We report a dichotomous TER response that generates two drug-discriminative populations
that are only revealed post amiloride. This group difference is further exemplified as different
profiles when the TER responses are normalised to either an initial baseline value, or re-
Variability of Trans-Epithelial Airway Resistance
PLOS ONE | DOI:10.1371/journal.pone.0149550 February 29, 2016 15 / 20
calculated at each drug addition step on a rolling baseline basis: both approaches are needed in
order to identify outliers, reflective of extreme response to a given drug or to drug combina-
tions. An example is given in S6 Fig with 99% confidence intervals shown in the shaded areas;
the outliers are clearly shown irrespective of whether the initial (panels A-I, A-II) or the rolling
baseline (panels B-I,B-II) is chosen as the starting value when calculating the ratio of changes.
Currently funded to study a rare inherited airway disease, Birt-Hogg-Dubé Syndrome [37],
we faced the problem of limited access to airway tissue. Therefore we focused on studying
apparently healthy volunteers to define a reference range of electrophysiological parameters, a
mandatory analysis prior to asking patients to volunteer for airway research studies [38–40].
In pilot work we tested the utility of our SOP in brushings from donors affected by different
diseases: three asthmatics, one BHD patient and four uninfected CF patients (homozygotes
F508del-CFTR). For the asthmatics and BHD patients we were able to expand, differentiate
(with an average of about twenty reconstituted epithelia for each donor) and analyse the
electrophysiological parameters of the resultant ALI cultures (data not shown). To our surprise,
none of the CF patient cells would attach and expand like either the controls or the disease-
affected subjects. Further work, outside the scope of the current paper, will have to establish
the cause (which was not due to bacterial or yeast infection).
By way of possible explanation, we note that over recent decades, many workers in the CF
field [41] report abnormalities in cellular networks that might explain such very unusual
growth characteristics in our CF brushings, consistent with the many independent pathways
that are abnormal after F508 is deleted from the CFTR protein [42,43]. For example, some of
these pathways centre on protein that binds to the first nucleotide binding domain of CFTR
and controls the signalling flux between the epidermal growth factor receptor and the assembly
of the scaffold which approximates MEK with ERK in the process of cell growth and
differentiation.
Thus our SOP could in future help determine the means to repair the abnormal pathways
that alter the production of epithelia from nasal brushings.
To this end, we present our range of values from our SOP that might help others navigate
the data obtained by different groups who often take polar opposite positions on which ion
transport characteristics are the principal drivers of pathophysiological change in a given dis-
ease. Importantly, we observe that a given individual can generate a mean/median in vitro
response that is reflective of their own set of ALIs as a whole, with the caveat that sufficient
numbers of cells must be harvested/cultured per nasal biopsy to permit sufficient ALIs to be
generated to compensate for seeding progenitor variability. We propose that a minimum of
5–6 ALIs per donor are necessary when performing ion transport experiments for better inter-
pretation and hope that our data will help different groups faced with the challenges of under-
standing the nature of the ‘normality challenge’ in their chosen disease. That challenge has
recently been set out in a review of the issues researchers will have to overcome to compensate
for the variability in the background on which disease occurs, which is the holy grail of person-
alised or precision medicine [44].
Supporting Information
S1 Fig. Effect of Na+ depletion on the electrophysiological properties of human airway epi-
thelia. (A) Recorded voltage from two different Ussing chamber experiments (donors C and
K) in which the epithelia were exposed to forskolin (FSK, 1μM) and then 50% of the buffer was
exchanged apically (white arrows) with NMDG+-HBSS (NaCl replaced with (NMDG+)Cl,
NaHCO3 with KHCO3 and Na2HPO4 with KH2PO4). For volume compensation the basolat-
eral side had the same 50% volume exchange but with standard HBSS. After stabilization, NaCl
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was added back by exchanging 50% of the buffer with standard HBSS (137.93 mMNaCl) for
three times (grey arrows). (B) Changes in V, TER and IEq at baseline (BAS.), after the addition
of forskolin (FSK) and at the different concentration of Na+ achieved after replacing each time
50% of the buffer in the apical chamber with the same volume of NMDG+-HBSS until 2.2mM
NaCl was reached.
(TIFF)
S2 Fig. Frequency distribution of TER values for all of the ALIs at baseline and after
manipulation of ion transport. (A) Relative frequency distribution of TER values at baseline
for all of the 137 ALIs analysed. The X-axes indicates the center of the bins in which the range
of all TER values have been divided. Each bin has a width of 200 Ocm2, meaning that the
range of each bin is “Bin center ± 100”. The Y-axes indicates the relative frequency (%) of ALIs
that fall into each bin. Relative frequency distribution at baseline and after the addition of
drugs (B-I) for the 44 ALIs analysed with drug regime I and (B-II) for the 81 ALIs analysed
with drug regime II.
(TIFF)
S3 Fig. Baseline values analysis at donor level.Mean baseline electrophysiological values of
(A) voltage, (B) resistance (TER) and (C) calculated equivalent current (V/TER[IEq]) from 18
donors (A-R) ranked in ascending order with respect to mean TER value. The data show nor-
mal distribution (Shapiro-Wilk test, P>0.05) for V and TER but not for V/TER[IEq]
(P<0.001).
(TIFF)
S4 Fig. Analysis of TER values upon drug addition. Before-after graphs of TER values from
(A-I) drug regime I and (A-II) drug regime II, showing the changes in TER for all of the indi-
vidual ALIs after each sequential drug addition. Mean TER values per donor (A-R, ranked in
alphabetic order as derived from Fig 3B in the manuscript) in (B-I) drug regime I and (B-II)
drug regime II. Data are presented as means ± SEM.
(TIFF)
S5 Fig. ALI-based analysis of TER ratio change upon drug addition. (A-I, A-II) Ratio of
TER change with drug regime I (n = 44) and II (n = 81) respectively, applying initial baseline
approach highlighting the cumulative effect of the drugs. (B-I, B-II) Same data analysed apply-
ing the rolling baseline approach to the TER values of individual ALIs. Error bars: mean ± 95%
CI.
(TIFF)
S6 Fig. Analysis of TER ratio at donor level (A-R) for the two drug regimes. (A-I, A-II)
Mean TER ratio in drug regime I (N = 13) and II (N = 18) respectively; donors ranked in
ascending order with respect to amiloride-induced change in TER (+AMI/BAS.), applying the
initial baseline approach. (B-I, B-II) Same as above with donors ranked in ascending order
with respect to amiloride-induced change in TER (+AMI/Inh172 in B-I and +AMI/BAS in
B-II.), applying the rolling baseline approach. Data shown as means ±SEM; Boxes: mean ±99%
CI for all ALIs.
(TIFF)
S7 Fig. Relationship between baseline voltage and change in TER after amiloride addition.
Baseline V plotted against ratio of TER upon amiloride addition in drug regime I (A-I, C-I),
and drug regime II (A-II). Second order polynomial regression was performed; line of regres-
sion with 99%CI (dotted lines). (B-I, D-I, B-II) Logarithm of baseline V plotted against TER
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ratio with amiloride.
(TIFF)
S1 File. Additional Methods: Study Approval, Cell culture additional considerations,
Immunofluorescence and Trans-epithelial resistance (TER). Table A. Mean baseline
electrophysiological values from Ussing chamber experiments of individual donors. Table B.
Regression and statistical analysis of Fig 5. Table C. Regression and statistical analysis of Fig 6.
Table D. Regression and statistical analysis of Fig 8. Table E. Mean TER values for Drug regime
I. Table F. Mean TER values for Drug regime II. Supporting Information References.
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